Michael Chansler

Company: Savid Therapeutics Inc.

Job title: Vice President, Business Development

Seminars:

Workshop C: From Pre-IND to IND – Overcoming Important Regulatory Hurdles to Get into the Clinic 9:00 am - 12:00 pm

Although traditional ADCs now have a developed regulatory framework, the regulatory pathway for next-generation conjugates is still developing. As more next-generation conjugates are being developed this will begin to become clearer, however, there still remains questions around the pre-IND and IND path, as well as core clinical and manufacturing regulatory challenges. This workshop will offer…Read more

day: Pre-Conference Day Track B

AMDC – Antibody Mimetic Drug Conjugates: Precision Engineered Medicines 1:45 pm

Discussing Cupid-Pysche: A novel and proprietary platform delivering a variety of payloads to multiple tumor associated antigen targets Analyzing a system for the rapid in vivo validation of antibody mimetic targeting ligands and the evaluation of therapeutic payloads including chemotherapeutics, immunotherapies, alpha emitting radioisotopes, and a proprietary photoimmunotherapyRead more

day: Scientific Program Day Two